1. Scripps Research Institute Scientists Identify First Potentially Effective Therapy for Human Prion Disease   
  2. Probe from SRIMSC Enters Phase II/III Clinical trials.   
  3. The Scripps Molecular Screening Center becomes the first to have 1000 AIDs in PubChem!   
  4. Receptos Scientists Publish Determination of a High Resolution S1P1 Structure in Science   
  5. NIH Common Fund researchers uncover structure of important target for drug design   
  6. NIH Research Matters: Designing New Diabetes Drugs   
  7. Discovery of a treatable mechanism for avoiding the deadly response to flu: North County Times, Eurekalert [1, 2]    
  8. Nature: Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand   
  9. Scripps Research and MIT scientists discover class of potent anti-cancer compounds    
  10. MLP Probe Project Leads to First in Human Studies    
  11. Business Wire:   Receptos Initiates Clinical Trials for S1P1 Agonist Program, Aimed at Multiple Sclerosis   
  12. Nature:   Quantitative reactivity profiling predicts functional cysteines in proteomes.

  13. Nature:   Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARc by Cdk5.
  14. Discovery and optimization of chemical probes to define important molecular signals in medicine.
  15. Nature Reviews Drug Discovery article:   Chemical modulators of S1P receptors as barrier-oriented therapeutic molecules.
  16. Nature Chemical Biology article: S1P1 signaling just keeps going and going and going…
  17. Nature Biotechnology article:   Identification of selective inhibitors of uncharacterized enzymes by high-throughput screening with fluorescent activity-based probes.
Home » MLPCN


The Molecular Libraries Probe Centers Network (MLPCN) is the full production phase replacement to the MLSCN. There are 4 large centers nationwide of which Scripps is one. Together with 5 speciality centers they comprise the MLPCN, a part of the NIH's strategic funding plan, the Roadmap Initiative.

To read the NIH MLPCN announcement, click here.

Assays are screened against compound libraries from the Molecular Libraries Small Molecule Repository (MLSMR). Information about the assays and molecules screened by the MLPCN is published to the PubChem public database.

Further information can be obtained from the following links;




PubChem PubChem


History (Pilot Phase)

The Molecular Libraries Screening Centers Network (MLSCN) was launched on June 15, 2005 as part of the Molecular Libraries Initiative (MLI). The MLSCN consisted of 10 screening centers with The Scripps Research Institute a leading member of the network.



Useful Links

Eli Lilly and NCGC Assay Guidance Manual

Documents & Definitions

Access to MLPCN Screening

FAQs for the MLPCN


Copyright (c) 2008-2011 TSRI.